Abstract
Second-line treatment of patients with metastatic renal cell carcinoma (MRCC) progressing under therapy with biological response modifiers (BRM) is an unresolved issue. Thirty-seven patients with MRCC progressing under treatment with BRM received vinorelbine i.v. at a dose of 30 mg/m2 q 22 days and 4,800,000 IU interferon (IFN)-alpha2c s.c. thrice weekly. Partial remission (PR) occurred in 8% of patients, stable disease (SD) (median duration 8, range 3-35+ months) was observed in 46% of patients. Median overall survival was 15 (range 1-49) months. No major toxicities occurred. Patients with MRCC who failed first-line treatment with BRM had a high chance to enter PR or SD under combined, low-toxic therapy with vinorelbine and IFN-alpha2c.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Austria / epidemiology
-
Carcinoma, Renal Cell / mortality
-
Carcinoma, Renal Cell / secondary
-
Carcinoma, Renal Cell / therapy*
-
Female
-
Humans
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / therapeutic use*
-
Immunotherapy
-
Infusions, Intravenous
-
Injections, Subcutaneous
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / therapeutic use*
-
Kidney Neoplasms / mortality
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / therapy*
-
Male
-
Middle Aged
-
Recombinant Proteins
-
Salvage Therapy
-
Survival Analysis
-
Treatment Outcome
-
Vinblastine / administration & dosage
-
Vinblastine / analogs & derivatives*
-
Vinblastine / therapeutic use
-
Vinorelbine
Substances
-
Antineoplastic Agents, Phytogenic
-
Immunologic Factors
-
Interferon-alpha
-
Recombinant Proteins
-
Vinblastine
-
Vinorelbine
-
interferon alfa-2c